Global Healthcare and Life Sciences dealmaking remained resilient in H1 2026 despite a more selective capital deployment environment in Q2. R&D partnerships generated 327 deals worth $172.6B with $9.4B in upfront cash and equity. Although deal volume moderated, the quarter was highlighted by Bristol Myers Squibb’s potential $15.2B collaboration with Hengrui Pharma across oncology, hematology, and immunology, Pfizer’s up to $10.5B oncology alliance with Innovent Biologics focused on ADCs and multispecific antibodies, and Fosun Pharma’s up to $4.7B option agreement for AriBio’s Phase III Alzheimer’s disease candidate AR1001. M&A activity reached 305 transactions totaling $194.1B, including contingents, led by Sun Pharma’s $11.8B acquisition of Organon to strengthen its women’s health and biosimilars business, Merck’s $11.3B acquisition of Bio-Techne to expand its life sciences tools and diagnostics capabilities, and AbbVie’s $10.9B acquisition of Apogee Therapeutics to reinforce its immunology and respiratory pipeline.
Venture financing remained resilient, with 612 rounds raising $27.7B, highlighted by Isomorphic Labs’ $2.1B AI drug discovery financing, NewLimit’s $435M longevity platform raise, and Korsana Biosciences’ approximately $380M financing to advance blood-brain barrier technology for Alzheimer’s disease. Public market activity also strengthened, with 27 IPOs raising approximately $7.4B, led by Parabilis Medicines’ $771M precision oncology offering, GMR Solutions’ $479M healthcare services IPO supporting balance sheet optimization, and Kardigan’s $460M raise to advance late-stage cardiovascular therapies. Overall, Q2 2026 highlighted continued momentum behind differentiated science, AI-enabled drug discovery, neuroscience, oncology, immunology, cardiovascular innovation, and strategically important healthcare platforms.
Â
Global Healthcare and Life Sciences R&D Partnerships
Global Healthcare and Life Sciences R&D partnership activity remained robust in H1 2026, with 327 deals generating $172.6B in total deal value and $9.4B in upfront cash and equity. Activity moderated in Q2 compared with Q1, as deal volume declined 18.3% to 147 from 180. However, total deal value fell just 4.5% to $84.3B from $88.3B, highlighting the market’s resilience despite fewer transactions. Upfront cash and equity declined more sharply by 22.6% to $4.1B from $5.3B, while average upfront payments decreased 22% to $84M from $108M. Median upfront payments also halved to $25M from $50M, indicating fewer transactions with large upfront commitments and a more measured funding environment. Robust H1 overall, with Q2 signaling fewer deals and tighter capital discipline.
Prominent Global Healthcare and Life Sciences R&D Partnerships in Q2 2026
Hengrui Pharma development and commercialization deal with Bristol Myers Squibb (BMS) – May 2026
Hengrui Pharma granted Bristol Myers Squibb exclusive worldwide rights, excluding China, Hong Kong, and Macau, to develop and commercialize 13 early-stage oncology, hematology, and immunology programs spanning Hengrui and BMS assets, with Hengrui retaining co-development options for up to 5 additional programs and reciprocal China rights on BMS-originated assets. Hengrui will lead early development through proof-of-concept before handover to BMS for global late-stage development and commercialization. Financial terms include up to $950M in staged payments ($600M upfront, $175M at year one, $175M in 2028) plus up to $14.3B in option fees, milestones, and tiered royalties outside China, Hong Kong, and Macau.
Innovent Biologics development and commercialization deal with Pfizer – May 2026
Innovent Biologics granted Pfizer exclusive worldwide rights to develop and commercialize 12 oncology programs, including 8 Innovent-originated assets and 4 Pfizer discovery-stage programs, focused on ADCs and multispecific antibodies. Innovent will lead discovery through Phase I across all programs, after which Pfizer will assume global late-stage development and commercialization. The portfolio is structured into three groups: 4 fully global Pfizer programs, 4 programs licensed ex-Greater China, and 4 co-developed programs with shared costs and co-commercialization in the US and Europe, while Innovent retains Greater China rights. Financial terms include a $650M upfront payment, up to $9.9B in milestones, and double-digit tiered royalties on product sales.
AriBio license option deal with Fosun Pharma for AR-1001 – May 2026
AriBio granted Fosun Pharma an exclusive worldwide option (excluding Korea, the Middle East, and Latin America) to develop, manufacture, and commercialize AR1001, a once-daily oral PDE-5 inhibitor in Phase III (POLARIS-AD) for Alzheimer’s disease. Upon exercise, Fosun gains full development and commercial rights in the licensed territories. AriBio is eligible for up to $4.7B in total consideration, including a $60M option fee, an additional $80M upon Phase III topline data (bringing staged payments to $140M), and a first $10M installment received on May 26, 2026. Additional upside includes sales milestones triggered at ≥$2.5B annual net sales and royalties of up to ~20%.
Global Healthcare and Life Sciences M&A
Global Healthcare and Life Sciences M&A activity remained strong in H1 2026, with 305 deals generating $194.1B in total M&A value, including contingents, and $151.8B in cash value excluding contingents. In Q2 2026, deal volume increased 14.8% to 163 from 142 in Q1, while total M&A value, including contingents, rose 34.7% to $111.4B from $82.7B, reflecting significantly higher transaction value alongside moderate growth in deal activity. Cash value excluding contingents also increased 12.6% to $80.4B from $71.4B. However, average upfront cash and equity per deal declined 27% to $1.3B from $1.8B, suggesting that Q1 was driven by a greater number of large upfront transactions, whereas Q2 activity was distributed across a broader set of deals. Median upfront value edged up 18.2% to $650M from $550M. Overall, H1 2026 reflected a healthy M&A market, with Q2 delivering higher deal volume and total transaction value.
Prominent Global Healthcare and Life Sciences M&A in Q2 2026
Sun Pharma acquiring Organon – April 2026
Sun Pharma announced the acquisition of Organon in April 2026, a commercial-stage company focused on women’s health, biosimilars, and established brands including Asmanex HFA, Fosamax, Hyzaar, Diprolene, Vtama, and Xaciato across asthma, osteoporosis, hypertension, dermatology, and bacterial vaginosis. The transaction, expected to close in early 2027, strengthens Sun Pharma’s global positioning toward top 25 pharma scale, expands its branded generics and innovative medicines footprint (27% share), enhances leadership in women’s health, and builds biosimilars scale (7th largest), while extending presence across 150 countries and 18 high-value markets. Financial terms include $14.00 per share in cash, implying approximately $11.8B enterprise value (including $8.6B debt and $574M cash), and a 24% premium to the last closing price.
Merck acquiring Bio-Techne – June 2026
Merck announced the acquisition of Bio-Techne in June 2026, a life sciences tools and diagnostics company spanning research reagents, analytical instruments, and diagnostic solutions, including R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics. The transaction, expected to close in late 2026 or early 2027, strengthens Merck’s position in multi-omics, spatial biology, and precision diagnostics through integration of Bio-Techne’s platform and commercial portfolio. Merck targets approximately EUR 140M in annual cost synergies by year three, with the deal expected to be earnings accretive. Financial terms include $73 per share in cash, representing a 24% premium to the prior close and a 36% premium to the one-month VWAP, implying an enterprise value of $11.3B, funded via cash and new debt financing.
AbbVie acquiring Apogee Therapeutics – June 2026
AbbVie announced the acquisition of Apogee Therapeutics in June 2026, a clinical-stage immunology company led by APG777 (zumilokibart), a Phase II, half-life extended monoclonal antibody targeting IL-13 for atopic dermatitis, with planned Phase III initiation in 2H 2026 and additional Phase I programs in asthma and eosinophilic esophagitis. The pipeline also includes APG-279 (Phase I, combination with APG-990 in atopic dermatitis with 2H 2026 PoC data), APG-808 (Phase I asthma), and APG-273 (preclinical combination with APG-333, a TSLP inhibitor, for asthma and COPD). The acquisition expands AbbVie’s immunology footprint and strengthens its position in respiratory and allergic disease indications, with closing expected in Q3 2026. Financial terms include $135.11 per share in cash, implying approximately $10.9B equity value and a 49% premium to the June 18, 2026, closing price.
Global Healthcare and Life Sciences Venture Activity
Global Healthcare and Life Sciences venture activity remained resilient in H1 2026, with 612 financing rounds raising a total of $27.7B. In Q2 2026, financing activity increased modestly, with the number of rounds rising 3% to 311 from 301 in Q1, reflecting sustained participation across the sector. Total funding, however, edged down 2% to $14B from $13.7B, indicating that while more companies secured financing, the average capital raised per round was slightly lower. Overall, H1 2026 reflected a stable venture financing environment, with Q2 sustaining healthy deal flow despite a decline in total capital raised.
Prominent Global Healthcare and Life Sciences Venture Activity in Q2 2026
Isomorphic Labs – Series B – $2.1B – May 2026
Isomorphic Labs raised a $2.1B series B to scale its AI-driven drug discovery platform, IsoDDE, and advance its internal pipeline toward clinical-stage development across multiple therapeutic areas and modalities. The company applies foundation-model AI to drug design and has established collaborations with major pharmaceutical partners, including Novartis, Eli Lilly, and Johnson & Johnson. Proceeds will be used to expand platform capabilities, accelerate pipeline programs, and strengthen computational infrastructure and global talent. The round was led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
NewLimit – Series C – $435M – June 2026
NewLimit raised a $435M series C to advance its epigenetic reprogramming platform aimed at restoring cellular function and addressing age-related diseases. Its lead programs target liver regeneration, vascular disease linked to chronic kidney disease, and T cell reprogramming for autoimmune indications. The financing will support the expansion of preclinical programs and progression toward first-in-human studies. The round was led by Founders Fund, with participation from Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Valor Equity Partners, and Eli Lilly Ventures.
Korsana – Private – $380M – April 2026
Korsana Biosciences secured approximately $380M through an oversubscribed private placement alongside a planned reverse merger with Cyclerion Therapeutics, creating a pathway to a Nasdaq listing under the ticker KRSA. The company is developing blood-brain barrier shuttle technology for neurodegenerative diseases, led by KRSA-028, a next-generation anti-amyloid antibody for Alzheimer’s disease designed to enhance CNS delivery while reducing treatment-related adverse events. The financing was backed by Fairmount, Venrock, General Atlantic, Wellington Management, RA Capital, RTW Investments, Forbion, Foresite Capital, and Sanofi Ventures. Proceeds are expected to fund operations into 2029 and support advancement of KRSA-028 into Phase I studies, while the reverse merger provides an expedited route to public markets without a traditional IPO.
Â
Global Healthcare and Life Sciences IPO ActivityÂ
Global Healthcare and Life Sciences IPO activity strengthened in H1 2026, with 27 IPOs raising approximately $7.4B in total proceeds. In Q2 2026, IPO activity increased 8% to 14 offerings from 13 in Q1, while total proceeds rose a stronger 47% to $4.4B from $3.0B. Overall, H1 2026 reflected improving public financing for healthcare, with Q2 showing stronger fundraising momentum and higher capital formation than in Q1.
Prominent Global Healthcare and Life Sciences IPO Activity in Q2 2026
Parabilis Medicines – IPO – $770.5M – May 2026
Parabilis Medicines completed a $771M IPO to advance its oncology pipeline built on the Helicon peptide platform, which targets traditionally undruggable intracellular proteins. Its lead asset, zolucatetide, targets the Wnt signaling pathway in desmoid tumors and has received FDA Orphan Drug and Fast Track designations. Proceeds will support late-stage clinical development and expansion of the company’s precision oncology pipeline. The IPO comprised 33.5 million shares priced at $20 per share, with the underwriters exercising their full option to purchase an additional 5.025 million shares. The transaction ranks among the largest biotechnology IPOs to date, reflecting demand for clinically de-risked, differentiated oncology platforms.
GMR Solutions – IPO – $478.7M – May 2026
GMR Solutions, the parent company of Global Medical Response, completed a $479M IPO to strengthen its balance sheet and reduce leverage. The company is the largest emergency medical services provider in the United States, operating air and ground ambulance transport, mobile healthcare, and disaster response services. Unlike traditional biotechnology issuers, the investment case is centered on healthcare services, stable recurring cash flows, and capital structure optimization rather than clinical development. The IPO was priced at $15 per share after a reduced pricing range, raising gross proceeds of $479M. Net proceeds, together with a concurrent private placement and existing cash, will be used primarily to redeem preferred equity and reduce outstanding debt, supporting deleveraging and a stronger post-listing financial profile.
Kardigan – IPO – $460M – May 2026
Kardigan raised $460M through its IPO to advance a late-stage cardiovascular pipeline targeting high-unmet-need heart diseases. Its programs include danicamtiv for genetic dilated cardiomyopathy, tonlamarsen for severe hypertension, and ataciguat for calcific aortic valve stenosis. Proceeds will support ongoing clinical development and preparation for key data readouts across multiple programs. The IPO comprised 28,750,000 shares priced at $16 per share, including the full exercise of the underwriters’ option.
Also check out Endocrine/Metabolic R&D Partnerships, Venture Funding and IPO Activity – Q1 2026 Review
